Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms

Chabot, Sophie ; Dizeyi, Nishtman LU ; Ramnemark, Lena ; Lluel, Philippe ; Abrahamsson, Per Anders LU and Grabe, Magnus LU (2021) In Phytomedicine Plus 1(4).
Abstract

Background: Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods: In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results: Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue... (More)

Background: Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods: In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results: Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin™ treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5α-reductase expression was observed in Cernitin™- and finasteride-treated animals. Conclusion: The current in vivo experiments support the use of Cernitin™ as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin™ on the management of chronic pelvic pain in men.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Benign prostatic hyperplasia, Cernilton®, Cernitin™, Cytokines, Prostatitis
in
Phytomedicine Plus
volume
1
issue
4
article number
100057
publisher
Elsevier
external identifiers
  • scopus:85125604973
ISSN
2667-0313
DOI
10.1016/j.phyplu.2021.100057
language
English
LU publication?
yes
id
1491eb3a-d705-497f-a03c-619b41f16540
date added to LUP
2022-04-13 16:16:58
date last changed
2022-06-22 04:51:29
@article{1491eb3a-d705-497f-a03c-619b41f16540,
  abstract     = {{<p>Background: Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods: In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results: Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin™ treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5α-reductase expression was observed in Cernitin™- and finasteride-treated animals. Conclusion: The current in vivo experiments support the use of Cernitin™ as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin™ on the management of chronic pelvic pain in men.</p>}},
  author       = {{Chabot, Sophie and Dizeyi, Nishtman and Ramnemark, Lena and Lluel, Philippe and Abrahamsson, Per Anders and Grabe, Magnus}},
  issn         = {{2667-0313}},
  keywords     = {{Benign prostatic hyperplasia; Cernilton®; Cernitin™; Cytokines; Prostatitis}},
  language     = {{eng}},
  number       = {{4}},
  publisher    = {{Elsevier}},
  series       = {{Phytomedicine Plus}},
  title        = {{Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms}},
  url          = {{http://dx.doi.org/10.1016/j.phyplu.2021.100057}},
  doi          = {{10.1016/j.phyplu.2021.100057}},
  volume       = {{1}},
  year         = {{2021}},
}